MOTS-c study reports retinal-barrier effects in cells and mice, not a treatment trial in people

A Cell Death Discovery paper published online on October 10 investigates the mitochondrial-derived peptide MOTS-c in diabetic retinopathy. The publisher labels it an Article in Press, shared before the final edited version. Treatment experiments used laboratory-grown human retinal endothelial cells and diabetic mouse models, not a human therapeutic trial.

The researchers report that MOTS-c treatment reduced retinal vascular leakage and helped preserve endothelial-barrier proteins in diabetic mice. In high-glucose cell experiments, they report improvements in barrier function and mitochondrial measures. These laboratory outcomes do not establish restored eyesight, reduced blindness or benefit in people with diabetic eye disease.

The paper links the observed effects to PLA2G6, an enzyme involved in phospholipid metabolism. Reducing PLA2G6 activity or expression weakened the protective effects in the tested models. This supports a proposed mechanism within the experiments; it does not establish that MOTS-c is an effective or approved medicine for diabetic retinopathy.

Human material consisted of vitreous eye-fluid samples from 11 patients undergoing surgery for diabetic retinopathy and 10 surgical patients with other eye conditions. The diabetic group was younger than the comparison group. The study measured MOTS-c levels in those samples; it did not administer MOTS-c to patients or assess a clinical treatment response. An association in collected samples cannot prove that replacing the peptide would treat the disease.

The authors describe systemic and local eye administration in animal experiments. These are research routes, not instructions for patients. They identify limitations including the lack of osmotic controls in the main high-glucose experiments, incomplete exclusion of other related enzymes and the need for more specific methods to study MOTS-c. Their findings do not settle human safety, appropriate use or long-term outcomes.

The work reports Chinese public and institutional research support, and the authors declare no competing interests. This brief is an evidence note about preclinical research, not a recommendation to buy, compound or use MOTS-c. It does not provide dosing or administration guidance. People with diabetes or vision changes should discuss established care with a licensed medical professional.